Agenus Inc (AGEN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.240.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AGEN
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on advancing botensilimab plus balstilimab (BOT+BAL) through clinical trials and regulatory pathways, including the Phase 3 ROBBIN trial in MSS colon cancer.
Stated as a priority in 3 of last 3 quarters. Agenus is advancing BOT+BAL through clinical development, including the Phase 3 ROBBIN trial enrolling 850 patients with MSS colon cancer, addressing 38,000 U.S. patients annually and a $7 billion sales opportunity. Clinical data from ~1,300 treated patients support this focus. The trajectory matches management's stated acceleration of BOT+BAL development and regulatory alignment.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Agenus reports advancement of Phase 3 ROBBIN trial of BOT+BAL in neoadjuvant MSS colon cancer.”
“Private placement supports strategic prioritization of BOT+BAL for neoadjuvant MSS colon cancer and advancement of ROBBIN trial.”
“BOT+BAL Phase 3 BATTMAN trial commenced patient enrollment; advancing clinical and regulatory readiness.”
Focus resources on neoadjuvant BOT+BAL treatment in high-risk Stage II/III MSS colon cancer, including discontinuing late-line metastatic BATTMAN trial support.
Stated as a priority in 2 of last 3 quarters. Agenus has shifted focus to neoadjuvant BOT+BAL in MSS colon cancer via the ROBBIN trial, discontinuing support for the BATTMAN late-line metastatic study. The private placement funds this prioritization with ROBBIN initiation and first patient dosing expected in Q1 2027. The trajectory reflects a clear strategic shift and resource prioritization.
“Agenus discontinued planned funding for BATTMAN Phase 3 study to focus on neoadjuvant ROBBIN trial.”
“Private placement supports strategic prioritization of BOT+BAL for neoadjuvant MSS colon cancer.”
Continue disciplined capital management, strengthen financial position, and support operations through strategic financing and collaborations.
Stated as a priority in 3 of last 3 quarters. Agenus strengthened its balance sheet via a strategic collaboration with Zydus providing $91 million upfront capital and manufacturing capacity, and an oversubscribed private placement raising $85 million upfront plus $255 million in warrants. Cash totaled $35 million at 2026-Q1. The trajectory shows disciplined capital allocation and balance sheet strengthening consistent with management's statements.
“Completed oversubscribed $85 million private placement with up to $255 million in milestone-aligned warrants.”
“Closed strategic collaboration with Zydus, delivering $91 million upfront capital and dedicated manufacturing capacity.”
“Continue disciplined capital allocation and strengthen balance sheet as a 2026 strategic priority.”
Broaden patient access to BOT+BAL through regulatory-authorized pathways and expand physician engagement and support infrastructure globally.
Stated as a priority in 2 of last 3 quarters. Agenus expanded BOT+BAL authorized access programs, increasing pre-commercial revenue from $4.6 million in 2026-Q1 to $6.4 million in 2026-Q2. Physician engagement broadened with BAP Pharma as global access partner. The trajectory shows delivery on expanding access and engagement.
“BOT+BAL access programs expanded across countries and institutions, contributing $6.4 million in pre-commercial revenue.”
“Physician engagement through regulatory-authorized access pathways continued to broaden; BAP Pharma named global access partner.”
Aim to reach positive net income as a financial milestone amid ongoing clinical and operational investments.
Stated as a priority in 3 of last 3 quarters. Net income showed volatility with $39.2 million positive in 2026-Q1 but negative $0.6 million in 2026-Q2. Operating income remained positive in recent quarters. The trajectory is mixed with limited progress toward consistent positive net income.
“Net income was negative $0.6 million in 2026-Q2 despite positive operating income.”
“Net income was positive $39.2 million in 2026-Q1.”
“Net income was negative $10.6 million in 2025-Q4.”
Over the trailing year it converted 1.41x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates (low R² over the window).
26 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.